Core Viewpoint - Wall Street analysts predict OPKO Health will report a quarterly loss of $0.11 per share, reflecting a year-over-year decline of 22.2%, with anticipated revenues of $155.14 million, down 14.7% from the previous year [1]. Group 1: Earnings Estimates - The consensus EPS estimate for the upcoming quarter has remained unchanged over the past 30 days, indicating analysts' reassessment of their initial projections [1][2]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [2]. Group 2: Revenue Projections - Analysts forecast 'Revenues- Revenue from transfer of intellectual property and other' to reach $14.89 million, indicating a year-over-year increase of 1.3% [4]. - The consensus estimate for 'Revenues- Revenue from products' is $42.96 million, reflecting a slight decline of 0.1% from the year-ago quarter [4]. - 'Revenues- Revenue from services' is projected to reach $97.29 million, showing a significant year-over-year decrease of 21.7% [4]. Group 3: Stock Performance - Over the past month, OPKO Health shares have returned +17%, contrasting with the Zacks S&P 500 composite's -1.8% change [5]. - OPKO Health currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [5].

Core Viewpoint - OPKO Health, Inc. is set to report its operating and financial results for the three and twelve months ending December 31, 2024, on February 27, 2025, after U.S. market close [1] Group 1: Financial Reporting - The financial results will be discussed during a conference call and live audio webcast scheduled for February 27, 2025, at 4:30 p.m. Eastern time [1] - Participants are encouraged to pre-register for the conference call to receive a unique PIN for immediate access [2] Group 2: Access Information - A telephone replay of the conference call will be available until March 6, 2025, with specific dialing instructions provided [3] - A webcast replay will be accessible approximately one hour after the live conference call [3] Group 3: Company Overview - OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing leading positions in rapidly growing markets through its expertise in discovery, development, and commercialization [4]

Core Insights - OPKO Health, Inc. will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco [1] - Management will host one-on-one meetings with investors and present on January 15 at 3:00 p.m. Pacific time, with the presentation available for live webcast and replay [1] Company Overview - OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing industry-leading positions in large, rapidly growing markets through its discovery, development, and commercialization expertise [2]

OPKO Health, Inc.’s (OPK) company, ModeX Therapeutics Inc., announced the dosing of the first participant in the Phase I study (NCT06655324) of an Epstein-Barr virus (EBV) vaccine candidate yesterday. The EBV vaccine is being developed in collaboration with Merck, which is known as MSD outside the United States and Canada.Per management, the first participant has been dosed with novel investigational EBV vaccine targeting multiple viral proteins in the Phase I study.It is worth mentioning that this developm ...

Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosisThere are no current treatments or vaccines for EBVFirst participant dosed with novel investigational EBV vaccine targeting multiple viral proteins in Phase I study WESTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), announces dosing of the first participant in the Phase I study (NCT06655324) of an EBV vaccine candidate bein ...

Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosisThere are no current treatments or vaccines for EBVFirst participant dosed with novel investigational EBV vaccine targeting multiple viral proteins in Phase I study WESTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), announces dosing of the first participant in the Phase I study (NCT06655324) of an EBV vaccine candidate being ...

OPKO Health, Inc. (OPK) delivered an earnings per share (EPS) of 3 cents in the third quarter of 2024 against the year-ago period’s loss of 11 cents per share and the Zacks Consensus Estimate of a loss of 10 cents per share.OPK’s Revenues in DetailOPKO Health registered revenues of $173.6 million in the third quarter, down 2.8% year over year. The figure missed the Zacks Consensus Estimate by 4.3%.Lower revenues from products and services dragged the overall top line.Shares of this company gained nearly 4.1 ...

For the quarter ended September 2024, OPKO Health (OPK) reported revenue of $173.6 million, down 2.8% over the same period last year. EPS came in at $0.03, compared to -$0.11 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $181.32 million, representing a surprise of -4.26%. The company delivered an EPS surprise of +130.00%, with the consensus EPS estimate being -$0.10.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wal ...

OPKO Health, Inc. (NASDAQ:OPK) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisor, IR Phillip Frost - Chairman and CEO Elias Zerhouni - Vice Chairman, President Adam Logal - CFO Conference Call Participants Maury Raycroft - Jefferies Yi Chen - H.C. Wainwright Edward Tenthoff - Piper Sandler Michael Petusky - Barrington Research Operator Good day, and welcome to the OPKO Health Third Quarter of 2024 Financial Results Conference Call. All partici ...

OPKO Health, Inc. (NASDAQ:OPK) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisor, IR Phillip Frost - Chairman and CEO Elias Zerhouni - Vice Chairman, President Adam Logal - CFO Conference Call Participants Maury Raycroft - Jefferies Yi Chen - H.C. Wainwright Edward Tenthoff - Piper Sandler Michael Petusky - Barrington Research Operator Good day, and welcome to the OPKO Health Third Quarter of 2024 Financial Results Conference Call. All partici ...